• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing?

作者信息

Gerber Andreas, Stock Stephanie, Dintsios Charalabos-Markos

机构信息

Institute for Quality and Efficiency in Health Care, Cologne, Germany.

出版信息

Pharmacoeconomics. 2011 Jul;29(7):549-53. doi: 10.2165/11592580-000000000-00000.

DOI:10.2165/11592580-000000000-00000
PMID:21671685
Abstract
摘要

相似文献

1
Reflections on the changing face of German pharmaceutical policy: how far is Germany from value-based pricing?对德国药品政策不断变化的面貌的思考：德国离基于价值的定价还有多远？
Pharmacoeconomics. 2011 Jul;29(7):549-53. doi: 10.2165/11592580-000000000-00000.
2
[Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].[德国的药品参考定价：治疗组的定义、通过回归程序设定价格及效果]
Gesundheitswesen. 2005 Jul;67(7):468-77. doi: 10.1055/s-2005-858485.
3
Do pharmaceutical prices respond to potential patient out-of-pocket expenses?药品价格会对患者潜在的自付费用做出反应吗？
Rand J Econ. 2002 Autumn;33(3):469-87.
4
Provider-administered drugs move to specialty pharmacy benefit.由医疗机构提供的药物转至专科药房福利范畴。
Manag Care. 2014 Apr;23(4):49.
5
The pricing and reimbursement of pharmaceuticals.药品的定价与报销
Pharmacoeconomics. 1994;6 Suppl 1:36-8. doi: 10.2165/00019053-199400061-00010.
6
Pricing of pharmaceuticals. Assessing the pricing potential by a pricing matrix model.药品定价。通过定价矩阵模型评估定价潜力。
Eur J Health Econ. 2004 Jun;5(2):110-5. doi: 10.1007/s10198-003-0209-y.
7
Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand.医疗保险药品参考定价：来自德国、荷兰和新西兰的证据。
Front Health Policy Res. 2004;7:1-54. doi: 10.2202/1558-9544.1050.
8
A survey of reimbursement practices of private health insurance companies for pharmaceuticals not covered under the Pharmaceutical Benefits Scheme 2008.一项关于私人健康保险公司对2008年《药品福利计划》未涵盖药品的报销做法的调查。
Aust Health Rev. 2011 May;35(2):204-10. doi: 10.1071/AH10894.
9
Pricing and reimbursement of pharmaceuticals. A new culture for the community pharmacist.药品定价与报销。社区药剂师的新文化。
Pharm World Sci. 1998 Jun;20(3):107-12. doi: 10.1023/a:1008651106315.
10
An analysis of capitation rates for prescription medication benefits from an insurance perspective.从保险角度对处方药福利的人头费率进行分析。
Benefits Q. 1991;7(3):52-61.

引用本文的文献

1
Acceptance of Evidence Transfer Within German Early Benefit Assessment of New Drugs for Pediatric and Adolescents Target Populations.德国针对儿童和青少年目标人群的新药早期效益评估中证据转移的接受情况。
Pharmacoeconomics. 2025 May;43(5):521-553. doi: 10.1007/s40273-024-01467-8. Epub 2025 Jan 17.
2
How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?在德国医保改革法案（AMNOG）实施十年后，德国距离基于价值的定价还有多远？
Appl Health Econ Health Policy. 2022 May;20(3):287-290. doi: 10.1007/s40258-021-00712-x. Epub 2021 Dec 29.
3
Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.

本文引用的文献

1
International prices and availability of pharmaceuticals in 2005.2005年药品的国际价格及可得性
Health Aff (Millwood). 2008 Jan-Feb;27(1):221-33. doi: 10.1377/hlthaff.27.1.221.
德国 1 型丙型肝炎病毒感染者使用索非布韦的成本效益：已发表结果的重新分析。
PLoS One. 2020 Oct 2;15(10):e0236543. doi: 10.1371/journal.pone.0236543. eCollection 2020.
4
Predictors of negotiated prices for new drugs in Germany.德国新药谈判价格的预测因素。
Eur J Health Econ. 2020 Sep;21(7):1049-1057. doi: 10.1007/s10198-020-01201-z. Epub 2020 May 25.
5
Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG.新药支付意愿：弥合 NICE 与 IQWiG 差距的一步。
BMC Health Serv Res. 2020 Apr 22;20(1):343. doi: 10.1186/s12913-020-5050-9.
6
A proportional rule for setting reimbursement prices of new drugs and its mathematical consistency.新药定价的比例规则及其数学一致性。
BMC Health Serv Res. 2020 Mar 23;20(1):240. doi: 10.1186/s12913-020-5055-4.
7
The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany.在德国进行早期效益评估后，添加性或替代性临床研究设计对肿瘤药物协商报销的影响。
Health Econ Rev. 2020 Mar 14;10(1):7. doi: 10.1186/s13561-020-00263-2.
8
Determinants of Orphan Drug Prices in Germany.德国孤儿药价格的决定因素。
Pharmacoeconomics. 2020 Apr;38(4):397-411. doi: 10.1007/s40273-019-00872-8.
9
Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World.癌症药物定价与报销：来自世界各地给美国的经验教训。
Oncologist. 2016 Aug;21(8):907-9. doi: 10.1634/theoncologist.2016-0106. Epub 2016 Jul 6.
10
Early decision-analytic modeling - a case study on vascular closure devices.早期决策分析模型——血管闭合装置的案例研究
BMC Health Serv Res. 2015 Oct 27;15:486. doi: 10.1186/s12913-015-1118-3.